Lenbelintide
AZD6234 · AstraZeneca
Selective amylin receptor agonist, including an adjunctive Phase 3 strategy.
Results availability
No numerical study results are currently summarized for this profile. The development stage and linked studies are listed below.
Mechanism at a glance
Obesity stage by formulation
Latest: SELENE 1–3 Phase 3 obesity/overweight protocols registered by AstraZeneca.
Next: Enrollment and Phase 3 obesity outcomes.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 3 studies3 records
SELENE 1
Weight management without type 2 diabetesWeight management without type 2 diabetes.
SELENE 2
Weight management with type 2 diabetesWeight management with type 2 diabetes.
SELENE 3
Weight managementAdjunct to incretin treatment.
Phase 2 studies2 records
APRICUS
Weight managementCompleted Phase 2 study of lenbelintide in overweight/obesity; no registry results posted.
ARAY
Weight managementCompleted Phase 2 study of lenbelintide in overweight/obesity; no registry results posted.
